Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease
2019
Abstract Background and aims
Polycystic liver diseaseis the most common extra-renal manifestation of
autosomal dominant polycystic kidney disease(ADPKD). There is need for robust long-term evidence for the volume-reducing effect of somatostatin analogues. We made use of data from an open-label, randomized trial to determine the effects of
lanreotideon height-adjusted liver volume (hTLV) and combined height-adjusted liver and kidney volume (hTLKV) in patients with ADPKD. Methods We performed a 120-week study comparing the reno-protective effects of
lanreotidevs standard care in 305 patients with ADPKD (the DIPAK-1 study). For this analysis we studied the 175 patients with
polycystic liver disease, with hepatic cysts identified by magnetic resonance imaging and liver volume ≥2000 ml. Of these, 93 patients were assigned to a group that received
lanreotide(120 mg subcutaneously every 4 weeks) and 82 to a group that received standard care (blood pressure coKN2ntrol, a sodium-restricted diet, and anti-hypertensive agents). The primary endpoint was percentage change in hTLV between baseline and end of treatment (week 120). A secondary endpoint was change in hTLKV. Results At 120 weeks, hTLV decreased by 1.99% in the
lanreotidegroup (95% CI, –4.21 to 0.24) and increased by 3.92% in the control group (95% CI, 1.56–6.28). Compared to controls,
lanreotidereduced the growth of hTLV by 5.91% (95% CI, –9.18 to –2.63; P P =.04).
Lanreotidereduced growth of hTLKV by 7.18% compared with controls (95% CI, –10.25 to –4.12; P Conclusion In this subanalysis of a randomized trial of patients with
polycystic liver diseasedue to ADPKD,
lanreotidefor 120 weeks reduced the growth of liver and combined liver- and kidney volume. This effect was still present 4 months after the last injection of
lanreotide. ClinicalTrials.gov no: NCT01616927
Keywords:
-
Correction
-
Source
-
Cite
-
Save
31
References
13
Citations
NaN
KQI